New cancer drug MBRC-101 enters human trials for Hard-to-Treat tumors

NCT ID NCT06014658

Recruiting now Disease control Sponsor: MBrace Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing MBRC-101, a drug that seeks out cancer cells and delivers a chemotherapy payload directly to them. It is for people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then check for side effects and signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MBRC-101 (an antibody-drug conjugate that targets EphA5 and delivers a chemotherapy drug called MMAE)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early, first-in-human trial with only 130 participants, so the drug may not prove effective or may cause significant side effects. Many similar antibody-drug conjugates fail in later testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Carolina BioOncology Institute
ACTIVE_NOT_RECRUITING

Huntersville, North Carolina, 28078, United States
Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States
Comprehensive Cancer Center of Nevada
RECRUITING

Las Vegas, Nevada, 89169, United States
Fox Chase Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19111, United States
Horizon Oncology Research
COMPLETED

Lafayette, Indiana, 47905, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Medical University of South Carolina (MUSC)
RECRUITING

Charleston, South Carolina, 29425, United States
NEXT Oncology
RECRUITING

Austin, Texas, 78758, United States
NEXT Oncology
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
PRISMA Health, Institute for Translational Oncology
RECRUITING

Greenville, South Carolina, 29605, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08903, United States
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITING

San Francisco, California, 94158, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Colorado, Anschutz Cancer Pavilion (ACP(
RECRUITING

Aurora, Colorado, 80045, United States
University of Pennsylvania, Abramson Cancer Center
RECRUITING

Philadelphia, Pennsylvania, 19014, United States
Winship Cancer Institute, Emory University
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.